The effect of PD-L1 status on survival outcomes in patients with stage II-III non-small cell lung cancer treated with chemotherapy

Karaca M., Tural D., Akar E., Unal D., Bayraktaoglu M., AKYÜREK N., ...Daha Fazla

JOURNAL OF BUON, cilt.25, sa.1, ss.268-273, 2020 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 25 Sayı: 1
  • Basım Tarihi: 2020
  • Dergi Adı: JOURNAL OF BUON
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, EMBASE, MEDLINE
  • Sayfa Sayıları: ss.268-273
  • Anahtar Kelimeler: lung cancer, NSCLC, immunotherapy, PD-1, PD-L1, DEATH-LIGAND 1, PROGNOSTIC-FACTOR, PULMONARY ADENOCARCINOMA, CLINICAL-SIGNIFICANCE, PROTEIN EXPRESSION, DOCETAXEL, STATISTICS, MUTATIONS, NIVOLUMAB
  • Gazi Üniversitesi Adresli: Evet

Özet

Purpose: There are conflicting results in the literature about the relationship between PD-1/PD-L1 expression and prognosis in non-small cell lung cancer (NSCLC). The purpose of this study was to identify the relationship between NSCLC patients' clinicopathologic characteristics and PD-1/PD-L1 expression.